

Solange Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592160/publications.pdf>

Version: 2024-02-01

205
papers

25,467
citations

14655

66
h-index

7745

150
g-index

208
all docs

208
docs citations

208
times ranked

26796
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	4.2	22
2	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e264-e268.	2.6	17
3	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2022, 15, 141-157.	3.1	13
4	Targeting HER2-Mutant NSCLC "The Light Is On. <i>New England Journal of Medicine</i> , 2022, 386, 286-289.	27.0	11
5	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. <i>Journal of Clinical Oncology</i> , 2022, 40, 598-610.	1.6	94
6	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
7	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	1.2	5
8	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
9	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	7.7	2
10	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1800-1808.	7.0	26
11	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	7.1	48
12	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	2.0	9
13	Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2022, 239, 586-589.	0.5	0
14	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
15	Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9023-LBA9023.	1.6	4
16	EORTC-1416-LCG/ETOP 8-15 "PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8512-8512.	1.6	14
17	Setting the Benchmark for KRAS ^{G12C} -Mutated NSCLC. <i>New England Journal of Medicine</i> , 2022, 387, 180-183.	27.0	1
18	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 259-268.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
20	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773.	1.1	128
21	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	7.0	70
22	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 375-386.	13.7	638
23	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Oncolmunology</i> , 2021, 10, 1860586.	4.6	40
24	Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets. <i>Cell</i> , 2021, 184, 571-573.	28.9	3
25	Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 318-326.	1.1	24
26	Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression. <i>Cancer Discovery</i> , 2021, 11, 1490-1507.	9.4	67
27	GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. <i>Cancer Research</i> , 2021, 81, 2345-2357.	0.9	65
28	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 85-88.	1.7	8
29	Severity of COVID-19 in patients with lung cancer: evidence and challenges. , 2021, 9, e002266.		78
30	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
31	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	13.2	198
32	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. <i>Cancer Discovery</i> , 2021, 11, 1330-1335.	9.4	3
33	The Promising Evolution of Targeted Therapeutic Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 810-814.	9.4	10
34	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	1.6	147
35	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1666-1678.	2.8	6
36	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. <i>JMIR Research Protocols</i> , 2021, 10, e30090.	1.0	7
38	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	1.1	37
39	Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 704295.	2.8	1
40	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.	2.6	10
41	Neutrophils in the era of immune checkpoint blockade. , 2021, 9, e002242.		52
42	Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 892-898.	1.1	7
43	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2040-2050.	1.1	26
44	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	3.8	23
45	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. <i>EJNMMI Research</i> , 2021, 11, 79.	2.5	11
46	Imaging Features of Pulmonary Immune-related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1449-1460.	1.1	8
47	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	7.1	42
48	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	1.6	183
49	Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC — The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. <i>Lung Cancer</i> , 2021, 161, 76-85.	2.0	4
50	Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study. <i>Translational Lung Cancer Research</i> , 2021, 10, 93-103.	2.8	21
51	⁶⁸ Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. , 2021, 9, e003594.		30
52	Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. <i>Scientific Reports</i> , 2021, 11, 20890.	3.3	3
53	Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navigator Programme. <i>European Journal of Oncology Nursing</i> , 2020, 44, 101714.	2.1	6
54	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays and cross-validation with resections, in patients with, stage III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	5.5	28

#	ARTICLE	IF	CITATIONS
55	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	16.8	6
56	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020, 150, 90-96.	2.0	18
57	Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272095745.	2.1	1
58	Gender gap: surveying the world for tomorrow. <i>ESMO Open</i> , 2020, 5, e000805.	4.5	6
59	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	4.5	18
60	Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. <i>Frontiers in Oncology</i> , 2020, 10, 578895.	2.8	17
61	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1248-1257.	1.8	33
62	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	9.4	108
63	Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. <i>Cancer Cell</i> , 2020, 38, 624-625.	16.8	35
64	Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 4208-4218.	1.6	30
65	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. <i>ESMO Open</i> , 2020, 5, e000820.	4.5	96
66	The METeoric rise of MET in lung cancer. <i>Cancer</i> , 2020, 126, 4826-4837.	4.1	29
67	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	16.8	51
68	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	1.1	82
69	Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. <i>Annals of Oncology</i> , 2020, 31, 1056-1064.	1.2	337
70	Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients. <i>Medical Physics</i> , 2020, 47, 4045-4053.	3.0	23
71	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
72	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	1.6	410

#	ARTICLE	IF	CITATIONS
73	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
74	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
75	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
76	Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. <i>Health Science Reports</i> , 2020, 3, e160.	1.5	8
77	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 144, 10-19.	2.0	14
78	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	10.7	247
79	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	1.1	34
80	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. <i>Lung Cancer</i> , 2020, 142, 114-119.	2.0	28
81	Targeting MET in EGFR resistance in non-small-cell lung cancerâ€”ready for daily practice?. <i>Lancet Oncology</i> , The, 2020, 21, 320-322.	10.7	19
82	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , 2020, 37, 738-741.	16.8	46
83	Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. <i>ERJ Open Research</i> , 2020, 6, 00165-2019.	2.6	24
84	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€”Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	7.1	446
85	Challenges in lung cancer therapy during the COVID-19 pandemic. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 542-544.	10.7	88
86	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	16.8	196
87	Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. <i>ESMO Open</i> , 2020, 5, e000796.	4.5	38
88	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9001-9001.	1.6	17
89	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016.	1.6	27
90	Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced <i>ALK</i>+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9518-9518.	1.6	18

#	ARTICLE	IF	CITATIONS
91	Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).. Journal of Clinical Oncology, 2020, 38, LBA110-LBA110.	1.6	15
92	Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.. Journal of Clinical Oncology, 2020, 38, LBA111-LBA111.	1.6	34
93	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. Journal of Clinical Oncology, 2020, 38, e15095-e15095.	1.6	3
94	Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1403.	7.1	7
95	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. Journal of Molecular Diagnostics, 2019, 21, 756-767.	2.8	37
96	Optimizing panel-based tumor mutational burden (TMB) measurement. Annals of Oncology, 2019, 30, 1496-1506.	1.2	123
97	Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology, 2019, 30, 1914-1924.	1.2	120
98	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer, 2019, 138, 79-87.	2.0	29
99	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	1.1	189
100	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
101	Nivolumab plus Ipilimumab in Advanced Non-“Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	27.0	1,866
102	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European Journal of Cancer, 2019, 109, 28-35.	2.8	69
103	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1859-1868.	6.4	62
104	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer, 2019, 134, 127-140.	2.0	156
105	EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1190-1192.	1.2	4
106	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 2019, 16, 563-580.	27.6	1,235
107	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology, 2019, 14, 1086-1094.	1.1	99
108	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-“Small Cell” Lung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	1.1	324

#	ARTICLE	IF	CITATIONS
109	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	2.0	40
110	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	1.2	78
111	Implementation of the Symptom Navi [®] Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi [®] Pilot Study). <i>BMJ Open</i> , 2019, 9, e027942.	1.9	5
112	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
113	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.	7.0	159
114	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	1.2	214
115	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	1.2	1,742
116	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2691-2698.	7.0	78
117	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	30.5	579
118	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	10.7	149
119	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	1.2	60
120	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	1.1	21
121	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
122	RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 387-398.	1.1	18
123	PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. <i>Cancer Treatment Reviews</i> , 2018, 62, 39-49.	7.7	94
124	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3007-3014.	1.6	184
125	<i>EML4-ALK</i> Variant Affects <i>ALK</i> Resistance Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 1257-1259.	1.6	6
126	Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. <i>BMJ Open</i> , 2018, 8, e021203.	1.9	0

#	ARTICLE	IF	CITATIONS
127	Immune Checkpoint Inhibitors in the Management of Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 682-695.	3.8	35
128	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open, 2018, 3, e000422.	4.5	50
129	Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. Annals of Oncology, 2018, 29, 2033-2036.	1.2	28
130	Report on the status of women occupying leadership roles in oncology. ESMO Open, 2018, 3, e000423.	4.5	35
131	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation—Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of Thoracic Oncology, 2018, 13, 1897-1905.	1.1	68
132	Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of Oncology, 2018, 29, 2214-2222.	1.2	243
133	Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. Journal of Thoracic Oncology, 2018, 13, 1242-1244.	1.1	7
134	Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration. Journal of Nursing Scholarship, 2018, 50, 540-548.	2.4	18
135	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. Current Treatment Options in Oncology, 2018, 19, 37.	3.0	13
136	Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell, 2018, 33, 791-793.	16.8	20
137	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. Journal of Clinical Oncology, 2018, 36, 8510-8510.	1.6	20
138	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9043-9043.	1.6	45
139	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine, 2017, 5, 435-444.	10.7	172
140	First-Line Nivolumab in Stage IV or Recurrent Non—Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
141	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non—Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Journal of Thoracic Oncology, 2017, 12, 752-762.	1.1	17
142	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer, 2017, 111, 143-149.	2.0	57
143	Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study. European Journal of Oncology Nursing, 2017, 29, 106-114.	2.1	14
144	Immunotherapy for Unresectable Stage III Non—Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1986-1988.	27.0	40

#	ARTICLE	IF	CITATIONS
145	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
146	Alectinib versus Crizotinib in Untreated <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 829-838.	27.0	1,858
147	Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study. <i>PLoS ONE</i> , 2017, 12, e0180389.	2.5	14
148	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
149	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	24
150	Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8509-8509.	1.6	25
151	A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a <i>HER2</i> mutation: The ETOP NICHE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9070-9070.	1.6	21
152	Afatinib in patients with metastatic <i>HER2</i> -mutant lung cancers: An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9071-9071.	1.6	14
153	Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9098-TPS9098.	1.6	1
154	Seeking New Approaches to Patients With Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e477-e482.	3.8	2
155	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	4.5	11
156	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , 2016, 1, e000142.	4.5	95
157	Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. <i>Oncologist</i> , 2016, 21, 1176-1182.	3.7	7
158	Apnea-like suppression of respiratory motion: First evaluation in radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 220-226.	0.6	43
159	The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 139-162.	7.7	187
160	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	1.1	231
161	Emerging Options After Progression During Crizotinib Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 643-645.	1.6	5
162	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016, 1, e000118.	4.5	6

#	ARTICLE	IF	CITATIONS
163	CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).. Journal of Clinical Oncology, 2016, 34, TPS8578-TPS8578.	1.6	19
164	CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).. Journal of Clinical Oncology, 2016, 34, TPS8579-TPS8579.	1.6	20
165	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. Journal of Clinical Oncology, 2016, 34, TPS8571-TPS8571.	1.6	7
166	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology, 2015, 10, 1451-1457.	1.1	141
167	Treatment of pleural malignancies by photoinduction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities. Lasers in Surgery and Medicine, 2015, 47, 807-816.	2.1	5
168	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1396-1403.	1.1	76
169	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	1.2	308
170	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology, The, 2015, 16, 1651-1658.	10.7	170
171	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, The, 2015, 386, 1049-1056.	13.7	316
172	How much platinum-based chemotherapy is enough in NSCLC?. Nature Reviews Clinical Oncology, 2015, 12, 8-10.	27.6	4
173	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results from the EUHER2 cohort study.. Journal of Clinical Oncology, 2015, 33, 11076-11076.	1.6	0
174	Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial.. Journal of Clinical Oncology, 2015, 33, 8049-8049.	1.6	0
175	Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. Swiss Medical Weekly, 2015, 145, w14206.	1.6	10
176	Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. Journal of the International AIDS Society, 2014, 17, 19622.	3.0	3
177	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	1.2	210
178	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	1.6	163
179	Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Research, 2014, 24, 496-500.	1.2	16
180	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	1.2	246

#	ARTICLE	IF	CITATIONS
181	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
182	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	1.2	410
183	Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1289-1290.	10.7	1
184	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. <i>Cancer Treatment Reviews</i> , 2014, 40, 917-926.	7.7	134
185	Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. <i>Translational Oncology</i> , 2014, 7, 393-399.	3.7	27
186	ALK inhibitors in the treatment of advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2014, 40, 300-306.	7.7	152
187	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. <i>Cancer Treatment Reviews</i> , 2014, 40, 716-722.	7.7	123
188	Targeted therapy in NSCLC driven by HER2 insertions. <i>Translational Lung Cancer Research</i> , 2014, 3, 84-8.	2.8	52
189	Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 8087-8087.	1.6	0
190	Molecular profiling of non-small cell lung cancer by histologic subtype. <i>Journal of Clinical Oncology</i> , 2014, 32, 8057-8057.	1.6	0
191	Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 307-309.	2.2	1
192	Treatment and detection of ALK-rearranged NSCLC. <i>Lung Cancer</i> , 2013, 81, 145-154.	2.0	30
193	VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. <i>Lung Cancer</i> , 2013, 79, 59-64.	2.0	30
194	Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. <i>Clinical Cancer Research</i> , 2013, 19, 5749-5757.	7.0	113
195	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	1.6	572
196	Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 137-144.	2.4	22
197	Dramatic Response Induced by Vemurafenib in a <i>BRAF</i> V600E-Mutated Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e341-e344.	1.6	98
198	RANKing lung cancer bone metastasis. <i>Lung Cancer Management</i> , 2012, 1, 87-90.	1.5	0

#	ARTICLE	IF	CITATIONS
199	MET: a promising anticancer therapeutic target. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 314-326.	27.6	275
200	Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). <i>European Journal of Cancer</i> , 2012, 48, 377-384.	2.8	73
201	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. <i>Lancet Oncology</i> , The, 2009, 10, 785-793.	10.7	106
202	Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. <i>Melanoma Research</i> , 2008, 18, 220-224.	1.2	63
203	Analysis of Natural Variants of the Human Immunodeficiency Virus Type 1 gag-pol Frameshift Stem-Loop Structure. <i>Journal of Virology</i> , 2002, 76, 7868-7873.	3.4	51
204	Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein. <i>Journal of Virology</i> , 2001, 75, 9644-9653.	3.4	73
205	Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1209-1213.	1.1	117